游离DNA产前筛查染色体微缺失微重复综合征的系统综述
该系统综述纳入7项大型研究(共474189例妊娠、210例微缺失/微重复综合征病例),评估cfDNA筛查MMs的性能。加权合并阳性预测值约44.1%,假阳性率低于0.1%,但因阴性病例缺乏侵入性验证,无法确定检出率和阴性预测值。
要点
- cfDNA筛查MMs的合并阳性预测值约44.1%,假阳性率低于0.1%
- 阴性未做侵入性验证,检出率与阴性预测值无法确定
- 科学学会不推荐cfDNA作为MMs的一线筛查
核心结论
- cfDNA筛查MMs的合并阳性预测值约40%,范围29%至91%,总体假阳性率低于0.1%。
- 由于绝大多数阴性病例未行侵入性验证,检出率和阴性预测值无法确定。
研究设计与样本
- 系统综述,检索Medline、Embase和Cochrane Library(2000年至2020年1月)。
- 纳入报告cfDNA筛查MMs诊断性能的大型系列(>5000例)文章。
- 最终纳入7篇论文,共474189例妊娠和210例MMs病例。
主要发现
- 阳性病例中整体有486/678例(71.68%)获得诊断验证。
- 加权合并筛查阳性率为0.19%(95%CI 0.09-0.33)。
- 加权合并假阳性率为0.07(95%CI 0.02-0.15)。
- 加权合并阳性预测值为44.1(95%CI 31.49-63.07)。
临床怎么用
- cfDNA筛查MMs阳性时阳性预测值约44%,需侵入性诊断验证。
- 假阳性率低于0.1%,但阴性结果不能排除MMs。
局限性
- 未对未行侵入性检测的病例(绝大多数阴性病例)进行验证分析。
- 因此无法确定检出率和阴性预测值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM OF THE STUDY: Scientific Societies do not recommend the use of cell-free DNA (cfDNA) testing as a first-tier screening for microdeletion and microduplication syndromes (MMs). The aim of this study was to review the current available literature on the performance of cell-free DNA as a screening for MMs. METHODS: Medline, Embase and the Cochrane Library were searched electronically from 2000 to January 2020 and articles reporting the diagnostic performance of cfDNA screening for MMs in large (>5000 cases) series were included. Between-study heterogeneity and random effect model for screen positive rate (SPR), false positive rate (FPR) and positive predictive value (PPV) were calculated. RESULTS: We identified 42 papers, seven included, for a total of 474,189 pregnancies and 210 cases of MMs. Diagnostic verification of positive cases was available overall in 486 (71.68 %) of 678 cases. The weighted pooled SPR, FPR and PPV were 0.19% (95% CI = 0.09-0.33), 0.07 (95% CI = 0.02-0.15) and 44.1 (95% CI = 31.49-63.07). In conclusion, the pooled PPV of cfDNA testing in screening for MMs was about 40%, ranging from 29% to 91%, for an overall FPR <0.1%. CONCLUSIONS: No confirmatory analysis was available in cases that did not undergo invasive testing, which were the vast majority of cases with a negative test, and therefore, the DR and the negative predictive value cannot be determined.
引用
- Familiari A, Boito S, Rembouskos G, et al. Cell-free DNA analysis of maternal blood in prenatal screening for chromosomal microdeletions and microduplications: a systematic review. Prenat Diagn. 2021. PMID: 33710639. doi:10.1002/pd.5928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。